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Abstract
Background. Statins and angiotensin receptor blockers
(ARBs) are known to improve vascular dysfunction in pa-
tients with chronic kidney disease. However, these effects
have been inconsistent in dialysis patients. Moreover, it is
currently unknown whether adding statins to ARBs im-
proves vascular dysfunction better than ARB monotherapy
in these patients.
Methods. We conducted a prospective open randomized trial
to investigate the effects of statin add-on to ARB on vascular
protection in 124 nondiabetic patients undergoing peritoneal
dialysis (PD). Initially, all patients received 80 mg/day of
valsartan for 6 months. Excluding 10 patients who dropped
out during this period, patients were randomly assigned to
continue ARB treatment alone (n¼ 57) or to receive 10 mg/
day of rosuvastatin (n ¼ 57) added to ARB for the next 6
months. To assess vascular function, endothelium-dependent
vasodilation and arterial stiffness were determined by bra-
chial artery flow-mediated dilation (FMD) and brachial-ankle
pulse wave velocity (baPWV), respectively.
Results. Compared to baseline values, ARB treatment for the
first 6 months significantly improved FMD% (2.976 2.64 to
3.576 2.58 %, P< 0.001). In addition, there was a small but
significant decrease in baPWV during this period (1691.56
276.3 to 1635.0 6 278.6 cm/s, P ¼ 0.048). After random-
ization, add-on treatment further improved FMD% (3.57 6
2.73 to 4.246 2.77 %, P¼ 0.003), whereas ARB monother-
apy did not (P¼ 0.02 for between-group difference). Further
slight improvement in baPWV (1617.06 280.9 to 1528.96
266.8 cm/s, P ¼ 0.021) was observed only in the combined
treatment group (P¼ 0.28 for between-group difference).
Conclusions. Adding a statin to the ARB was of some help
in improving vascular dysfunction more effectively than
ARB monotherapy in nondiabetic PD patients. However,
whether such limited improvements can lead to better clin-
ical outcomes requires further investigation.
Keywords: angiotensin receptor blocker; arterial stiffness; endothelial
function; peritoneal dialysis; statin
Introduction
Functional changes in vascular endothelial cells and vascular
smooth muscle cells (VSMCs) influence large artery com-
pliance, thus arterial stiffness is strongly affected by endo-
thelial cell signaling and VSMC tone [1]. The changes in
arterial distensibility and stiffness in patients with chronic
kidney disease (CKD) are different from those in control
subjects [2]. Vascular changes are known to develop early
during the course of renal insufficiency and progress as kid-
ney function declines. In addition, vascular remodeling oc-
curs in response to increased hemodynamic burden, chronic
uremia, inflammation, oxidative stress and extensive vascu-
lar calcification caused by CKD progression [3]. Moreover,
these vascular abnormalities are reported to be independent
predictors of cardiovascular mortality in patients with end-
stage renal disease (ESRD) [4–7].
For >10 years, renin–angiotensin system (RAS) block-
ades and 3-hydroxy-3-methylglutaryl-CoA reductase in-
hibitors have been widely used to reduce cardiovascular
risk based on the results of many large-scale clinical studies
[8, 9]. In addition, these drugs are known to reduce inflam-
mation and oxidative stress and to improve vascular dys-
function in the general population as well as in CKD
patients prior to dialysis [10, 11]. Different from the gen-
eral population, however, whether such drugs are beneficial
in preventing cardiovascular events is not clear in patients
with CKD [12–14]. Although RAS blockades not only
delay the progression of kidney disease but also decrease
all-cause mortality in patients with CKD prior to dialysis,
their effect on cardiovascular mortality was not satisfactory
in this population [15, 16]. In addition, in patients
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undergoing hemodialysis, statin therapy failed to decrease
all-cause mortality [14] and cardiovascular events [17].
Nevertheless, RAS blockades and statins still constitute
the main therapeutic options for the treatment and preven-
tion of cardiovascular disease (CVD) in ESRD patients.
The morality rates of diabetic ESRD patients are signifi-
cantly higher than those of nondiabetic patients, mainly
because of preexisting severely compromised cardiovascu-
lar conditions [18]. Because diabetes is largely responsible
for the generation of oxidative stress and inflammation,
which are major culprits in vascular pathology [19], nondia-
betic ESRD patients are presumed to have different vascular
characteristics compared with those with diabetes on dialysis
despite the development and progression of vascular dysfunc-
tion caused by uremia per se [2]. In this regard, a fortifying
strategy for vascular protection is necessary to improve pa-
tient outcomes particularly in nondiabetic ESRD patients, but
this has been largely unexplored. In addition, there have been
few studies on the effects of RAS blockades and statins on
vascular function in these patients. Therefore, we undertook
this study to investigate whether adding a statin to an angio-
tensin II type 1 receptor blocker (ARB) may confer greater
vascular protection than ARB monotherapy in nondiabetic
patients undergoing long-term peritoneal dialysis (PD).
Subjects and methods
Study subjects
Between January 2008 and December 2008, 300 patients who were over 20
years of age and had been maintained on PD >3 months were screened for
this study. Because we were mainly concerned about the effects of com-
bined treatment of ARB and statin on vascular function in ESRD patients
with low-risk profiles for CVD, patients were considered eligible if they had
no diabetes and no previous history of cardiovascular comorbidities. In
addition, we excluded patients with overt infection during the last 3 months
prior to the study and a history of malignancy or other chronic inflammatory
disease, such as systemic lupus erythematosus or rheumatoid arthritis.
Among the screened patients, 124 patients who met the criteria and gave
informed consent were enrolled in this study (Figure 1). The study was
approved by the institutional review board for human research at our center
(2008–06).
Study design
We conducted a prospective, randomized, open-label trial. This study had an
open two-phase design. After a 4-week washout period, all patients (n ¼
124) were treated with a single ARB, 80 mg/day of valsartan for 6 months
prior to randomization because functional antagonistic effects of various
ARBs are different [20, 21] and it takes several months for the full effect
of RAS inhibition to show up. Excluding 10 patients who dropped out
during this first 6-month period, patients then were randomly assigned to
continue ARB monotherapy (n ¼ 57) or to receive add-on treatment with
10 mg/day of rosuvastatin (n ¼ 57) in addition to ARB for the next 6
months. Randomization was performed by a 1:1 ratio using computer-gen-
erated random numbers.
Data collection
Demographic and clinical data were recorded in the beginning of the
study: age, gender, body mass index (BMI) calculated as weight/(height)2,
primary renal disease, previous history of CVD and duration of dialysis.
CVD was defined as a history of coronary, cerebrovascular or peripheral
vascular disease. Following laboratory data were measured from blood
samples: hemoglobin, blood urea nitrogen, creatinine, albumin, calcium,
phosphorus, intact parathyroid hormone, total cholesterol, low-density
lipoprotein (LDL) cholesterol, high-density lipoprotein cholesterol and
triglyceride. Kt/V urea was determined from the total loss of urea nitrogen
in the spent dialysate using the Watson equation [22].
Flow-mediated dilation and nitroglycerin-mediated dilation
Endothelium-dependent vasodilation was assessed noninvasively by
determining flow-mediated dilation (FMD) using high-resolution ultra-
sound (Logiq 7; GE Medical Systems, Milwaukee, WI). Patients were
informed to fast overnight, not to exercise, not to ingest substances that
might affect FMD, such as caffeine, high-fat foods or vitamin C, and not to
Fig. 1. Flow of the study subjects through each stage of the study. DM, diabetes mellitus; SLE, systemic lupus erythematosus; HD, hemodialysis; KT, kidney
transplantation. *Rhabdomyolysis is defined as creatine kinase elevation less than five times the upper limit of normal (reference range 44 ~ 245 IU/L).
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smoke for at least 12 h before the study. The measurement protocol for
brachial artery (BA) FMD has also been described in detail elsewhere [23].
The BA-FMD and nitroglycerin-mediated dilation (NMD) were calculated
as the percentage increases in the BA diameter relative to the mean base-
line diameter during reactive hyperemia and after administration of nitro-
glycerine, respectively. All ultrasound measurements were performed by a
single observer who was blinded to patient information and treatment
allocation. Intraobserver within-subjects coefficient of variations for BA-
FMD and NMD were 5.5  0.7 and 7.7  1.3%, respectively.
Brachial-ankle pulse wave velocity
The baPWV was measured as described previously [24]. Electrocardio-
gram, bilateral brachial and ankle blood pressures (BP), and brachial and
post-tibial arterial pulse waves were simultaneously measured with avas-
cular testing device (VP-2000 PWV; Nippon Colin Ltd, Komaki, Japan).
Bilateral brachial and post-tibial arterial pressure waveforms were stored
for 10 s by extremities cuffs connected to a plethysmographic sensor and
an oscillometric pressure sensor wrapped on both arms and ankles. The
baPWV was calculated from the distance between two arterial recording
sites divided by transit time.
Assessment of volume status
Volume status was estimated by a multifrequency bioelectrical impedance
analysis (BIA) device (X-scan body composition analyzer; Jawon Medi-
cal, Kyungsan, Korea) with tetrapolar electrodes. BIA was performed
between both hands and ankles in an upright position. Both hands were
held at a 45 angle away from the body. X-scan uses 1, 5, 50, 250, 550 and
1000 kHz frequencies to analyze intracellular fluid, extracellular fluid
(ECF) and total body water (TBW). ECF was normalized to height and
TBW. The intra-examination coefficient of variation for BIA was 2.2%.
Measurement of serum inflammatory markers and oxidative stress
High-sensitive C-reactive protein (hs-CRP) and interleukin-6 (IL-6) were
determined using a latex-enhanced immunonephelometric method on a
BN II analyzer (Dade Behring, Newark, DE) and a commercially available
enzyme-linked immunoabsorbent assay (ELISA) kit (R&D Systems
Europe, Oxon, UK), respectively. Fibrinogen was measured in citrated
plasma by a modified clot-rate assay using a Pacific Hemostasis Assay
Set (Humlersville, NC). In addition, the concentration of 8-isoprostane, a
maker for oxidative stress, was measured by enzyme immunoassay
(Cayman Chemical, Ann Arbor, MI).
Power calculation
The number of patients needed to detect a 10% difference of brachial-ankle
pulse wave velocity (baPWV) between the two groups over 6 months with
two longitudinal measurements with a power of 90%, an a value of 0.05,
and a standard deviation of 240 was 47 patients per group. Considering a
dropout percentage of 20%, 59 patients were needed for each group.
Statistical analysis
Statistical analysis was performed using SPSS version 13.0 (SPSS, Inc.,
Chicago, IL). Data were expressed as mean SD or median with range for
the skewed data. In graphs, however, data were expressed as mean 
SEM. The Kolmogorov–Smirnov test was used to analyze the normality
of the distribution of parameters. Comparisons between the two groups
were made by the chi-square test and Student’s t-test for normally distrib-
uted variables. Paired t-test was used to determine the differences in the
measured parameters between the two periods. For skewed variables, the
Mann–Whitney U-test and Wilcoxon signed-rank test were conducted. In
addition, differences in FMD, NMD and baPWV were further compared
between statin add-on treatment group and ARB monotherapy group using
mixed-effects models. Post-treatment results were presented as an estimate
of the mean difference and 95% confidence interval (CI). A value of
P <0.05 was considered significant. All analyses were performed on an
intention-to-treat basis.
Results
Demographic and clinical data
Table 1 details the baseline characteristics of the 124
patients. The mean age was 48.8 years, and 44.4% were
male. The mean duration of dialysis was 76.7 months and
the mean BMI was 22.8 kg/m2. There were 83 anuric pa-
tients. Baseline laboratory data are presented in Table 2.
Effects of 6-month ARB treatment on vascular function
Compared with the baseline values, 6-month ARB
treatment significantly improved FMD (2.97  2.64 to
3.57  2.58 %, P < 0.001) but not NMD. There was a
small but significant decrease in baPWV (1691.5  276.3
Table 1. Patient characteristicsa
Number of patients 124
Age (years) 48.8 6 11.0
Gender (male:female) 55:69
BMI (kg/m2) 22.8 6 3.0
PD duration (months) 76.7 6 50.6
Biocompatible PD solution, n (%) 114 (92.3)
Primary disease, n (%)
Chronic glomerulonephritis 62 (50.0)
Hypertension 32 (25.6)
Polycystic kidney disease 3 (2.6)
Others 6 (5.1)
Unknown 21 (16.7)
Antihypertensive medications, n (%)
ACE inhibitors/ARBs 89 (71.8)
Beta blockers 69 (55.6)
Calcium channel blockers 82 (65.9)
Others 64 (51.5)
Active vitamin D treatment 41 (33.3)
aAll data were expressed as mean 6 SD. ACE, angiotensin-converting
enzyme.
Table 2. Changes of clinical and laboratory parameters during 6-months
ARB treatmenta
Baseline 6 Months
SBP (mmHg) 133.3 6 19.6 133.4 6 20.4
DBP (mmHg) 80.8 6 9.7 80.6 6 11.0
Haemoglobin (g/dL) 10.9 6 1.7 10.9 6 1.6
Calcium (mg/dL) 8.8 6 0.6 8.9 6 0.8
Phosphorus (mg/dL) 5.0 6 1.3 5.2 6 1.1
PTH (pg/mL) 295.8 6 134.9 264.1 6 109.1
Serum albumin (g/dL) 3.8 6 0.4 3.7 6 0.4
Total cholesterol (mg/dL) 186.9 6 36.6 184.0 6 40.0
Triglyceride (mg/dL) 106.5 (35.0–742.0) 95.0 (30.0–932.0)
HDL (mg/dL) 53.1 6 15.9 49.3 6 15.0
LDL (mg/dL) 115.4 6 32.8 115.5 6 31.5
Fasting glucose (mg/dL) 92.6 6 18.9 90.5 6 11.4
Serum fibrinogen (mg/dL) 488.0 6 91.1 467.4 6 105.5*
hs-CRP (mg/L) 1.98 6 1.42 1.53 6 1.11y
IL-6 (pg/mL) 7.42 6 2.81 7.00 6 5.56
8-Isoprostane (pg/mL) 335.0 (50.5–1986.9) 297.7 (16.9–1506.5)
Kt/V 2.14 6 0.38 2.12 6 0.44
Total UF volume (mL/day) 1080.5 6 490.3 1005.2 6 592.4
Urine volume (mL/day) 440.4 6 755.0 410.4 6 664.0
TBW (L) 35.1 6 6.7 35.0 6 6.6
ECF (L) 12.9 6 2.5 12.8 6 2.4
ECF/height (L/m2) 8.0 6 1.3 7.9 6 1.3
ECF/TBW 0.37 6 0.01 0.37 6 0.01
aAll data are expressed as mean 6 SD or median with range for skewed
data. SBP, systolic blood pressure; DBP, diastolic blood pressure; PTH,
parathyroid hormone; HDL, high-density lipoprotein, LDL; low-density
lipoprotein, hs-CRP; high-sensitivity C-reactive protein, IL-6; interleukin-
6, UF, ultrafiltration, TBW, total body water; ECW, extracellular water.
*P < 0.05 versus baseline, yP < 0.001 versus baseline.
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to 1635.0  278.6 cm/s, P ¼ 0.048) by ARB treatment
(Figure 2). In addition, hs-CRP (1.98  1.42 to 1.53 
1.11 mg/L, P < 0.001) and fibrinogen levels (488.0 
91.1 to 467.4  105.5 mg/dL, P ¼ 0.028) were
significantly decreased after 6-month ARB treatment. IL-
6 and 8-isoprostane levels also tended to decrease during
the first 6-month ARB treatment but did not reach statistical
significance (Table 2).
Effects of add-on treatment with statin to ARB on
vascular function
There were no significant differences in age, gender, BP
and lipid profiles between the ARB monotherapy and com-
bined groups (Tables 3 and 4). In addition, hs-CRP, IL-6,
fibrinogen and 8-isoprostane levels were comparable at the
time of randomization (Table 4).
Compared to the vascular function at 6 months, add-on
treatment further increased FMD by 18.7% (3.57  2.73 to
4.24 2.77 %, P ¼ 0.003), whereas ARB monotherapy did
not (Figure 2). In addition, add-on treatment but not ARB
monotherapy resulted in a slight but significant decrease in
baPWV by 5.5% (1617.0  280.9 to 1528.9  266.8 cm/s,
P ¼ 0.021). During this period, there was no significant
alteration in NMD in both treatment groups. In the
meantime, statin add-on treatment significantly decreased
total cholesterol (182.7  33.4 to 135.7  26.4 mg/dL,
P < 0.001) and LDL cholesterol levels (110.8  29.6 to
65.6  21.2 mg/dL, P < 0.001). In addition, serum hs-
CRP (1.63  1.10 to 1.24  0.87 mg/L, P ¼ 0.003), IL-6
(7.16  5.65 to 6.40  4.29 pg/mL, P ¼ 0.057) and 8-
isoprostane levels [317.5 (18.9–1506.5) to 193.2 (36.9–
542.1) ng/mL, P ¼ 0.07] were further decreased by the
combined treatment (Table 4).
We calculated the differences in FMD, baPWV, hs-CRP,
IL-6 and 8-isoprostane levels during this period and
compared these values between the two groups (Figure 3).
Compared to ARB monotherapy, the between-group differ-
ences in FMD% [0.66 (95% CI, 0.32–1.01) versus 0.10
(0.23 to 0.45), P ¼ 0.02] and hs-CRP levels [0.39
(95% CI, 0.61 to 0.17) versus 0.02 (0.23 to 0.19)
mg/L, P ¼ 0.02] were greater in the add-on treatment
group. The between-group differences in baPWV (P ¼
0.28), IL-6 (P ¼ 0.55) and 8-isoprostane (P ¼ 0.65) levels
were also greater in the combined treatment group but did
not reach statistical significance.
Discussion
Whether statins should be combined with ARBs to boost
vascular protection in CKD patients is controversial. Un-
fortunately, two recent, randomized, controlled, prospec-
tive studies showed that statin therapy did not decrease
all-cause mortality [14] and cardiovascular events [17] in
patients undergoing hemodialysis, suggesting that the
pathogenesis of vascular events in ESRD patients may be
different from those without ESRD and that earlier statin
therapy prior to initiating dialysis may be of benefit. Rele-
vant to this assumption are the results from the Anti-
Oxidant Therapy in Chronic Renal Insufficiency (ATIC)
study demonstrating that sequential antioxidant treatment
with statin, vitamin E and folic acid significantly improved
FMD in nondiabetic patients with mild-to-moderate CKD
without manifest CVD [11]. On the other hand, to date,
there have been only two studies in which ARB treatment
significantly improved arterial stiffness in patients on dial-
ysis [10, 25]. Interestingly, patients with diabetes and a
history of CVD were excluded in one study [10], and only
a small number of patients with diabetes was included in
the other [25]. With such a background in mind, in this
study, we hypothesized that vascular response to statins
and ARBs might be different between diabetic and non-
diabetic patients and between patients with and without
Table 3. Comparison of demographic and clinical data at randomization
between patients treated with ARB alone and those with combination of
ARB and statina
ARB alone ARB 1 statin
Number of patients 57 57
Age (years) 48.8 6 10.6 48.9 6 11.5
Gender, male (%) 29 (51.2) 26 (45.9)
BMI (kg/m2) 22.8 6 3.2 23.0 6 2.9
PD duration (months) 77.6 6 49.0 75.7 6 52.9
Biocompatible PD solution, n (%) 54 (95.1) 51 (89.2)
Antihypertensive medications, n (%)
Beta blockers 47 (82.1) 42 (73.0)
Calcium channel blockers 49 (85.3) 49 (86.4)
Others 36 (63.4) 34 (59.5)
Active vitamin D treatment 21 (36.6) 17 (29.7)
Fig. 2. (A, C and E) Changes of vascular function during 6-month ARB
treatment. Compared with the baseline, 6-month ARB treatment signifi-
cantly improved FMD and decreased baPWV. (B, D and F) Changes of
vascular function between the combined therapy and ARB monotherapy
group. Compared with the levels at 6 months, add-on treatment with statin
(solid line) further improved FMD and decreased baPWV by 15.6 and
5.4%, respectively, whereas valsartan alone did not (dashed line). *P <
0.05 versus baseline, yP < 0.01 versus baseline, zP < 0.01 versus base-
line. Error bars indicate SE.
Combined vascular effects of statin and ARB in ESRD patients 3725
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evident CVD. Thus, we excluded patients with diabetes
and a history of CVD. In addition, the patients in the
present study were characterized by young age, normal
range of BMI and relatively well-controlled BP. Moreover,
only 6.4% of our patients had LDL cholesterol levels over
160 mg/dL and 7.6% had triglyceride levels over 250 mg/
dL. These findings indicate that our patients were at a rel-
atively low risk of CVD. To investigate whether add-on
treatment with statin to ARB may confer a greater vascular
protection in such patients, we conducted a comprehensive
assessment of vascular function, including endothelial-
dependent vasodilation and arterial stiffness. As a result,
we found that compared to ARB monotherapy, add-on
treatment further improved endothelial dysfunction. In ad-
dition, arterial stiffness was slightly but significantly im-
proved by adding a statin to an ARB, suggesting that
combined treatment with a statin and ARB may be of some
help in improving vascular dysfunction in these patients.
In this study, we further investigated on parameters asso-
ciated with vascular function. During the first 6-month ARB
treatment, hs-CRP levels were significantly decreased by
23% from baseline. Adding a statin to an ARB further de-
creased hs-CRP levels by 24%, whereas ARB monotherapy
alone did not. Other markers such as fibrinogen, IL-6 and 8-
isoprostane showed similar trends but the decreases were
more prominent in the combined treatment group. These
findings can explain the possible mechanism responsible
for the partial improvement in vascular dysfunction in our
study. A number of studies have stressed the importance of
inflammation and oxidative stress in the development of
atherosclerosis and arteriosclerosis [26]. In line with these
studies, our study showed improved vascular function along
with the decreased levels of the abovementioned markers.
Therefore, it can be presumed that systemic inflammation
and oxidative stress play an important role in the
Table 4. Changes of clinical and laboratory parameters after randomizationa
ARB alone ARB 1 statin
6 Months 12 Months 6 Months 12 Months
SBP (mmHg) 132.3 6 20.5 132.6 6 17.1 134.6 6 20.5 132.0 6 16.6
DBP (mmHg) 80.2 6 10.3 80.0 6 10.9 80.9 6 11.9 78.9 6 8.0
Hemoglobin (g/dL) 11.2 6 1.5 10.8 6 1.2 10.66 1.6 10.4 6 1.4
Calcium (mg/dL) 8.8 6 0.8 8.7 6 0.9 9.0 6 0.9 8.9 6 1.0
Phosphorus (mg/dL) 5.1 6 1.0 5.1 6 1.3 5.2 6 1.1 5.0 6 1.0
PTH (pg/mL) 293.5 6 184.2 252.46190.4 231.5 6 95.6 232.0 6 89.5
Serum albumin (g/dL) 3.8 6 0.4 3.8 6 0.4 3.7 6 0.4 3.8 6 0.5
Total cholesterol (mg/dL) 185.2 6 46.1 197.6 6 48.1 182.7 6 33.4 135.7 6 26.4y
Triglyceride (mg/dL) 97.0 (35.0–932.0) 113.0 (45.0–976.0) 94.0 (30.0–564.0) 86.0* (23.0–454.0)
HDL (mg/dL) 50.7 6 16.5 48.3 6 16.4 47.8 6 13.2 49.7 6 14.8
LDL (mg/dL) 120.2 6 32.8 121.4 6 37.4 110.8 6 29.6 65.6 6 21.2y
Fasting glucose (mg/dL) 90.5 6 13.0 89.8 6 17.5 90.6 6 9.4 87.8 6 9.1
Serum fibrinogen (mg/dL) 467.7 6 98.5 430.6 6 75.7* 467.0 6 114.0 417.9 6 64.1z
hs-CRP (mg/L) 1.43 6 1.14 1.41 6 1.10 1.63 6 1.10 1.24 6 0.87z
IL-6 (pg/mL) 6.87 6 5.54 6.67 6 5.25 7.12 6 5.65 6.40 6 4.29
8-isoprostane (pg/mL) 277.1 (16.9–1270.7) 265.9 (61.8–3816.3) 318.0 (18.9–1506.5) 193.2 (36.9–542.1)
Kt/V 2.11 6 0.47 2.09 6 0.50 2.13 6 0.41 2.11 6 0.44
Total UF volume (mL/day) 1035.1 6 550.3 1030.8 6 488.7 982.2 6 421.4 1015.1 6 445.8
Urine volume (mL/day) 405.9 6 612.6 375.9 6 609.5 428.6 6 721.2 395.2 6 557.3
TBW (L) 35.5 6 6.3 35.8 6 7.0 34.9 6 7.1 34.8 6 6.8
ECF (L) 13.0 6 2.3 13.2 6 2.6 12.8 6 2.6 12.9 6 2.5
ECF/height (L/m2) 8.0 6 1.2 8.1 6 1.4 7.9 6 1.4 8.0 6 1.4
ECF/TBW 0.36 6 0.04 0.37 6 0.05 0.37 6 0.01 0.37 6 0.01
aSBP, systolic blood pressure; DBP, diastolic blood pressure; PTH, parathyroid hormone; UF, ultra filtration.
*P < 0.05 versus 6 months, yP < 0.01 versus 6 months, zP < 0.001.
Fig. 3. Between-group differences between ARB monotherapy group and
combination therapy group (closed squares ARB monotherapy, open
squares ARB 1 statin). The differences in FMD and hs-CRP were bigger
in the combined treatment group than in ARB monotherapy group. *P <
0.05 versus ARB monotherapy. Error bars indicate SE.
3726 S.H. Han et al.
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on N
ovem
ber 24, 2013
http://ndt.oxfordjournals.org/
D
ow
nloaded from
 
development of vascular dysfunction and correction of these
detrimental factors is required to recuperate vascular
function.
Even though both statin and ARB improved vascular dys-
function in our patients, the degrees of improvement of endo-
thelial dysfunction and arterial stiffness in these patients were
relatively smaller than those without CKD in the previous
studies [27, 28]. In general, the tunica intima of the arterial
wall is made up of one layer of endothelial cells, and the
tunica media is composed of VSMC that are surrounded by
collagen and elastic fibers [1]. In addition, it is well known
that endothelium-derived nitric oxide (NO) is a major phys-
iological regulator of vascular tone and functional and struc-
tural changes in vascular endothelial cells and VSMCs
influence large artery compliance [1]. Meanwhile, in patients
with ESRD, oxidative stress and inflammation are increa-
sed in the systemic circulation and are major culprits of
decreased NO bioavailability [29]. These patients are also
characterized by extensive vascular calcification in the in-
tima, media and elastic fibers of the arterial wall [3]. There-
fore, such alterations in the vessels can lead to endothelial
and smooth muscle dysfunction, eventually leading to in-
creased arterial stiffness. To date, however, neither statins
nor ARBs have been proven to attenuate the rate of pro-
gressive vascular calcification [30, 31]. Taken together, it
can be surmised that statins and ARBs can improve endo-
thelial dysfunction by decreasing oxidative stress and in-
flammation in an altered vascular milieu but are of limited
help in improving global arterial function because of con-
siderable calcific burden in VSMCs and the surrounding
elastic fibers in ESRD patients. These can partly explain
attenuated vascular response to these drugs in our study.
Alternatively, such limited vascular response to ARB and/
or statin may be attributed to the unique patient characteristics
in this study. Most patients had been on long-term PD with a
mean duration of 76.7 months. As the ATIC study suggested,
the vascular response to such therapy could be different
if patients were treated in earlier stages of CKD [11]. In
addition, all patients in this study were nondiabetics. Whether
statins are as effective in diabetic patients as they are in
nondiabetic patients is still under debate. However, the
Cholesterol Treatment Trialists’ Collaborators suggested that
statins were equally effective in reducing vascular events
among patients with or without diabetes [32]. Further studies
will be necessary to clarify whether statins would still remain
effectual in the ESRD population.
It has been reported that vascular function can be
considerably affected by diverse factors, such as volume
status [33], residual renal function [34] and hypertension
[35]. To address this issue, volume status and residual urine
volume were monitored during the follow-up period and
were found to be unchanged and comparable between the
two groups. In addition, patients maintained BP at stable
levels during the study period. During the washout period,
other antihypertensive medications were prescribed to con-
trol BP, thus no significant changes in BP were observed
during the follow-up. Therefore, the improvement of vas-
cular function in this study was unlikely to be attributed to
the influence of these factors.
Several shortcomings should be discussed in this study.
First, this study is limited by the small number of patients
and high dropout rates. As described in the Subjects and
Methods section, the sample size was calculated before
the start of the study. We assumed that a total of 118
subjects would be required to detect 10% difference of
baPWV with a dropout percentage of 20% taken into ac-
count. However, at the end of study, the actual difference
in baPWV between the two groups was <10% and the
dropout rate exceeded 20%. This may explain a lack of
statistical power for the between-group difference of
baPWV in this study despite a significant decrease in
baPWV during 6–12 months only in the combined treat-
ment group. Further studies with a larger sample size or a
cross-over design would overcome this limitation.
Second, we did not evaluate dose-dependent changes in
FMD or baPWV. In the present study, since serum lipid
levels in our patients were not so high, 10 mg of
rosuvastatin was selected. Whether vascular dysfunction
could be further improved by escalating the dose of statin is
currently unknown. However, such effects can be expected
because there is some evidence that inflammation is more
ameliorated by a high dose of statin [36]. Third, this study
included only nondiabetic PD patients who did not have
cardiovascular cormobidities and were considered to have
low cardiovascular risk. Because diabetes is the most com-
mon cause of ESRD and CVD is prevalent in ESRD patients
[37], it needs to be verified whether our data with such a
specific patient cohort can be generalized to other popula-
tions. Finally, more detailed information is needed to explain
the weak vascular response to statins and ARBs. We eval-
uated the effects of these drugs on vascular function with
respect to decreasing inflammation and oxidative stress,
which are well-known strengths of these drugs. However,
as aforementioned, the drugs failed to inhibit the progression
of vascular calcification. Therefore, further studies on
therapeutic strategies for attenuating vascular calcification
would be helpful to delineate the relationship between com-
plex vascular pathophysiology and arterial compliance in
ESRD patients.
In conclusion, this study demonstrated that combined
treatment with a statin and an ARB was more effective in
improving endothelial dysfunction compared with ARB
monotherapy in nondiabetic PD patients. However, there
was only a slight improvement in arterial stiffness by add-
on treatment with statins. Therefore, whether such limited
improvements in vascular dysfunction can lead to better
clinical outcomes needs to be further investigated.
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